MicroRNA-146 attenuates lipopolysaccharide induced ovarian dysfunction by inhibiting the TLR4/NF-κB signaling pathway

Fengping He⁎, Yanhui Liu⁎, Tang Li, Qiulin Ma, Zhang Yongmei, Peiqing He, and Chuanyin Xiong⁎

⁎Affiliated Dongguan Maternal and Child Health Hospital, Southern Medical University, Guangzhou, China; ⁎Affiliated HuaDu Hospital, Southern Medical University, Guangzhou, China

ABSTRACT
Premature ovarian insufficiency (POI) is a disease that seriously affects women's reproductive function and even leads to lifelong infertility. Little is known about the mechanism of lipopolysaccharide (LPS)-induced ovarian dysfunction. Thus, we aimed to identify the role of the up-regulation of microRNA (miRNA)-146 expression offered protection against ovarian dysfunction by inhibiting the toll-like receptor (TLR) 4, TLR4/phosphorylated (p)-nuclear factor (NF)-κB signaling pathway and inflammatory cytokine tumor necrosis factor (TNF)-a and Interleukin (IL)-6. In an in vivo study, we established an LPS-induced ovarian dysfunction mouse model. The mouse ovarian granulosa cells were transfected with miR-146 mimic or negative controls or inhibitor and then treated with LPS. Therefore, cell viability, cells apoptosis, IL-6 and TNF-a, TLR4, NF-κB were assessed, respectively. These results demonstrated that the up-regulation of miRNA-146 expression may protect against LPS-induced ovarian dysfunction and markedly increased the cell viability, and significantly reduced the ovarian granulosa cells apoptotic rate, and down-regulated IL-6 and TNF-a expression. In addition, miRNA-146 exerted protective ovarian functions might be via inhibiting TLR4/NF-κB signaling pathway. In summary, we reveal the up-regulation of miRNA-146 expression mitigated ovarian dysfunction by negatively regulating expression of the IL-6 and TNF-a, which may shed light on the potential molecular mechanisms of overexpression of miRNA-146 may reversed the ovarian dysfunction by inhibiting the TLR4 / NF-κB signaling pathway.

ARTICLE HISTORY
Received 27 January 2022
Revised 19 April 2022
Accepted 22 April 2022

KEYWORDS
miRNA-146; lipopolysaccharide (LPS); ovarian insufficiency (POI); apoptosis; ovarian dysfunction

CONTACT Fengping He tongxun029@126.com Affiliated Dongguan maternal and Child Health Hospital, Southern Medical University, Guangzhou, 523125, China; Chuanyin Xiong xiongcy3001@163.com Affiliated HuaDu Hospital, Southern Medical University, Guangzhou, China

⁎Co-first author: Yanhui Liu

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Highlights
- First of all, the new mice model of POI were established by LPS-induced ovarian dysfunction.
- The up-regulation of miRNA-146 may protect against LPS-induced ovarian dysfunction.
- The up-regulation of miRNA-146 was markedly increased the granulosa cells viability.

Introduction

Primary ovarian insufficiency (POI) usually refers to women’s amenorrhea before the age of 40, accompanied by elevated serum follicle-stimulating hormone (FSH) and decreased estrogen (E2) levels [1,2]. The loss of ovarian function leads to amenorrhea and atrophy of sexual organs and inhibits follicular growth and development [1]. POI also includes premature ovarian failure (POF) [2]. POI is a disease commonly, which seriously affects women’s reproductive function, even leads to lifelong infertility, affects mental and physical health, and brings great pain to individuals and families. Women under the age of 40 account for 1–2%, and young women under the age of 30 account for 0.1% [3]. The etiology of POI is unclear, and its pathogenesis is very complex, which has not been clarified so far. In POI and POF, inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin (IL) – 6 lead to apoptosis of ovarian granulosa cells and ovarian dysfunction [4]. Therefore, inhibiting inflammatory response and granulosa cell apoptosis and protecting ovarian function from damage are effective therapeutic strategies for POI.

MicroRNAs (miRNAs) are 18–22 nucleotides in length, single-stranded, non-coding RNA molecules, which participate in the occurrence and development of diseases by specifically binding with target mRNA, leading to the degradation of target mRNA or inhibiting its translation process. They are naturally important gene regulatory molecules [5–7]. miRNA-146 has been confirmed participates in regulation of innate immune, including inflammation and oxidative stress [8]. Moreover, previous studies demonstrated lipopolysaccharide (LPS) and toll-like receptor (TLR) 4 existence on ovarian granulosa cells from human preovulatory follicles, and the LPS-dependent activation of TLR4 can induce ovarian granulosa cells apoptosis [9]. Furthermore, LPS can directly act on the ovaries, including follicular components such as the theca and granulosa cells or oocytes. LPS is recognized by a specific receptor complex: TLR 4, which is a signal transducer of LPS, is a component of the outer membrane of gram-negative bacteria. Ligation of TLR-4 by LPS leads to activation of nuclear factor kappa B (NF-κB) and consequently transcription of pro-inflammatory cytokines and chemokines [10]. Studies have also found that bovine ovarian granulosa cells can initiate an inflammatory response to LPS via the TLR4 pathway [9–11]. In addition, granulosa cells respond to LPS and increased the levels expression of interleukin (IL) 6 and IL8 [12]. miRNA-146 could directly regulate bacterial LPS messenger, so as to reduce the sensitivity of LPS and playing an anti-inflammatory and anti-apoptotic role [9]. However, in the LPS-treated POI model, the effect of miRNA-146 protection against ovarian dysfunction and ovarian granulosa cells apoptosis was explored by suppressing TLR4/ NF-κB signaling pathways.

Therefore, we hypothesize that LPS-induced ovarian dysfunction and lead to female infertility. The aim of this study was to understand the potential molecular mechanism of miRNA-146 protection against LPS-induced ovarian dysfunction. We constructed and verified the protective effect of miRNA-146 suppressing TLR4/ NF-κB signaling pathways by LPS-induced ovarian dysfunction of POI model. Our goal is to provide a novel therapeutic targets of POI.

Materials and methods

Animals

Female BALB/c mice (8 weeks; 18–22 g) were obtained from the Animal Laboratory of Sun Yat-sen University. The mice were fed in an environment with temperature of 22 ± 2°C, humidity of 50 ± 5%, light of 12 hours and darkness of 12 hours, and adaptive feeding for one week. All animal experiments were approved by the Animal Experiment Ethics Committee of Sun Yat Sen University (NO.SYSU-IACUC-2020-B1236).
Establishment of mouse premature ovarian failure model

According to references [13,14], POI mouse model was established by injecting LPS (0.8 mg/kg), \( n = 20 \). The establishment of the model was carried out by the Animal Laboratory of Sun Yat sen University. The mice were through the caudal vena cava injection with LPS (0.8 mg/kg) for 7 days. After 10 days, blood samples were collected in dry test tubes without coagulant to obtain the serum. The concentration of estradiol (E2) and FSH in blood samples was tested by Chemiluminescence. According to gold-standard diagnostic of POI in the levels of the main ovarian hormones is (low estradiol (E2) 100 pmol/L and follicle-stimulating hormone (FSH) of 25 IU/L) [15].

Induction of POI in mice by LPS-induced and injection of miRNA-146-mimics Female BALB/c mice \( n = 6 \) aged 8 weeks were purchased from the Animal Laboratory of Sun Yat sen University. The mice were randomly divided into the following two groups (6 mice/group): the miRNA-146 mimics group, which was intravenously administered 100 μmol/L (20 μl/mL) through the caudal vena cava injection for 7 days. And the Scramble miRNA group, which intravenously administered 100 μmol/L of Scramble miRNA (20 μl/mL) through the caudal vena cava injection for 7 days. After 15 days, blood samples were collected in dry test tubes without coagulant to obtain the serum. The concentration of estradiol (E2) and FSH in blood samples was tested by chemiluminescence.

Isolation of mice granulosa cells and LPS treatment

According to references [16], mice ovarian granulosa cells were obtained from BALB/c mice \( n = 6 \) of the Animal Laboratory of Sun Yat sen University (Guangzhou, China). The female BALB/c mice ovaries were quickly dissected under sterile conditions and put into pre-cooled PBS to remove the surrounding tissues and surface capsule. Under the anatomical microscope, the follicles were punctured with a syringe needle to release the mice ovarian granulosa cells into DMEM-F12 medium, which were blown and dispersed into a single suspended cell in a centrifugal tube. Second, the ovarian granulosa cells were incubated at 37°C, 5% CO₂ for 24 h, after which 1 mg/ml 0.25% trypsin and 0.02% EDTA were added. Subsequently, the ovarian granulosa cells were incubated in an 37°C, 5% CO₂ for another 60 min and filter them with a 200 mesh stainless steel cell sieve.

The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich; Merck KgaA), 100 U/ml penicillin G (Shanghai, China), 100 μg/ml streptomycin (Shanghai, China) and 2 mM glutamine (Guangzhou, China). Lipopolysaccharide (LPS) was purchased from Shanghai (Shanghai Bioengineering Co., Ltd, China). Ovarian granulosa cells were cultured in CO₂ incubator (37°C, saturation humidity, 5% CO₂). Under serum-free conditions for 24, the granulosa cells were treated with LPS under different conditions (4, 8, 12, 16, 20 μg/mL).

Cell transfection

miRNA-146 mimics (30 nmol/L), miRNA-146 Inhibitors (30 nmol/L), negative control (NC), and siRNA TLR4-specific targeting were all purchased from Shenggong Gene Company (Shanghai, China). Cell transfection was performed with Lipofectamine 3000 transfection reagent in strict according to the manufacturer’s instructions (Chagan, Germany). All transfection cells with 30 nmol/L of miRNA-146 mimics or 30 nmol/L of miRNA-146 inhibitors for 24 hours were collected for further study.

MTT assay

The cell viability was analyzed by 3-(4,5-dimethylthiazole-2-yl) – 2,5-diphenyl-2- tetrazole ammonium bromide (MTT) colorimetry. In short, miR-146 transfected granulosa cells were inoculated at a density of \( 1 \times 10^3 \) cells/well, and then the cells were cultured with LPS for 24 hours. After rinsing twice with phosphate buffered saline (PBS), 10 μl MTT solution was added to each well with a final concentration of 5 mg/mL. The culture dish was cultured at 37°C for 10 min and 4 h, then 150 μl of dimethyl sulfoxide was added, and the absorbance was determined after shaking the plate for 10 min. Each experiment was repeated three times.
Apoptosis assay

The apoptosis of ovarian granulosa cells was analyzed using terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay (Roche, Germany). For each sample, eight visual fields were randomly selected. The apoptotic index was calculated for 100 ovarian granulosa cells by dividing the number of apoptotic ovarian granulosa cells by the total number of ovarian granulosa cells.

The expression levels of miRNA-146 in mice blood samples and ovarian granulosa cells were detected by PCR

After the ovarian tissue was ground with liquid nitrogen, miRNA was reverse-transcribed and amplified, cDNA synthesis kit and SYBR Green PCR Master Mix kit were used, and U6 was used as the control of miRNA. All operations were carried out on ice to avoid RNase pollution. The Applied Biosystems ABI 7500 (USA) system was used for real-time fluorescence quantitative PCR. The reaction conditions were as follows: pre-denaturation at 95°C for 10 min, denaturation at 95°C for 15 s, annealing at 55°C for 15 s, 35 cycles. The relative expression of miR-146 was calculated by 2-ΔΔ CT. The primer sequence is shown in Table 1.

TNF-a, IL-6, TLR4, and NF-kB protein expression in ovarian granulosa cells were detected by western blot

Ovarian granulosa cells from ovarian tissues were treated by sonication, the lysates of cells were centrifuged and the proteins were separated by SDS-PAGE and then transferred to Immobilon-NC membranes (Millipore, USA). After 2 h 5% skim milk blockage with Tris- buffered saline at room temperature, the membrane was incubated with primary antibodies against TLR4, NF-kB, IL-6, TNF-a, and β-actin overnight at 4°C. Then, membranes were incubated with secondary antibodies conjugated with horseradish peroxidase for 1 h at 37°C. Blots were imaged using a Bio-Rad imaging system (Bio-Rad, USA).

Statistics

SPSS 19.0 was used to analyze the data which are presented as the mean ± standard error of the mean (SEM). One-way analysis of variance with a Bonferroni’s post hoc test was performed for multiple comparisons. P < 0.05 was considered to indicate a statistically significant difference.

Results

The expression of miRNA-146, E2, FSH and ROS in POI model

Firstly, in this experiment, the levels of miRNA-146 expression were significantly decreased in POF model, compared with the control group, detected by qRT-PCR analyzed (Table 2). And the concentration of Estradiol (E2) and FSH was determined by using Chemiluminescence analyzed, respectively. The concentration of E was significantly reduced and FSH significantly enhanced in POI model (Table 2). Then, the levels of ROS expression were

| Table 1. The sequence of primers. |
|----------------------------------|
| Primer name | Primer sequence |
| miR-146-F | 5’-ACCAGCAGCTCTTGATGC –3’ |
| miR-146 R | 5’-GACGAGCTGCTCAAGTTCC –3’ |
| U6-F | 5’- CTCCCCGCCGGAACACA-3’ |
| U6-R | 5’- AAGGTCCAGAATTGGCT-3’ |

| Table 2. Comparison of miRNA-146, E2, FSH and ROS levels between the two groups by injection of miRNA-146 mimics in POI model (x±s). |
|----------------------------------|
| Groups | n | miRNA-146 | E2 (pmol/L) | FSH (IU/L) | ROS (ng/ml) |
| Control | 6 | 3.06 ± 0.32 | 137.69 ± 23.91 | 13.82 ± 2.42 | 12.92 ± 4.72 |
| POI | 6 | 2.93 ± 0.28 | 98.51 ± 19.26 | 24.51 ± 7.42 | 17.15 ± 5.36 |
| t | - | 6.534 | 10.178 | 12.566 | 8.472 |
| P | - | 0.08 | 0.011 | 0.018 | 0.013 |

| Table 3. Comparison of miRNA-146, E2, FSH and ROS levels between the two groups by injection of miRNA-146 mimics in POI model (x±s). |
|----------------------------------|
| Groups | n | miRNA-146 | E2 (pmol/L) | FSH (IU/L) | ROS (ng/ml) |
| Control | 6 | 3.06 ± 0.32 | 137.69 ± 23.91 | 13.82 ± 2.42 | 12.92 ± 4.72 |
| POI | 6 | 1.66 ± 0.19 | 68.51 ± 19.26 | 57.51 ± 18.17 | 38.06 ± 9.83 |
| t | - | 20.168 | 18.293 | 16.897 | 10.573 |
| P | - | 0.000 | 0.000 | 0.000 | 0.000 |
measured by ELISA assay and significantly increased in POI model (Table 2). The effects of miRNA-146 mimics on FSH and E2 for 7 days of tail vein injection in mice are shown in Table 3; the concentration of E was significantly increased and FSH significantly decreased in POI model.

**miRNA146 down-regulation in LPS induces of POI model**

In mouse POI model, firstly we examined the ovarian dysfunction of mouse treated with LPS and the levels of miRNA-146 expression. LPS treatment significantly decreased the cell viability measured by CCK8 assay. miRNA-146 expression was decreased in POI model by LPS-induced compared with the control group detected by PCR (shown in Tables 2 and 3). In addition, we measured the levels of miRNA-146 expression in ovarian granulosa cells and the significant endogenous down-regulation were detected in the LPS group (shown in Figure 2). Moreover, to explore the role of miRNA-146 protective against in LPS-induced ovarian dysfunction, we increased miRNA-146 expression by miRNA-146 mimics and a negative control (NC) in LPS-treated ovarian granulosa cells. Cell viability was significantly increased, and the TNF-a and IL-6 were decreased in the miRNA-146 group compared with the LPS group (shown in Figures 1 and 2).

![Figure 1. LPS suppresses viability of granulosa cells.](image1)

![Figure 2. Transfection efficiency of miRNA-146 in granulosa cells. a: miRNA-146 mimics, inhibitors and transfection efficiency. The expression levels of miRNA-146 in granulosa cells and negative control group were detected by PCR. GAPDH is quality control, *** P < 0.001.](image2)
**Expression of miRNA-146 and granulosa cells viability**

To detect the expression of miRNA-146 in granulosa cells and the effect of ovarian granulosa cells viability on LPS-induced ovarian dysfunction and the oxidative status of ovarian granulosa cells. We detected the effect of miRNA-146 and studied the viability of ovarian granulosa cells treated with different concentrations of LPS (4, 8, 12, 16, and 20 µg/mL) for 12, 24, 36, and 48 hours by CCK8 assay (Figure 1b). Therefore, select 12 µg/mL was used as LPS stimulant as the following experimental conditions. ROS level was increased in ovarian granulosa cells stimulating used LPS compared with the control group (shown in Table 2). We found that the levels of miRNA-146 expression aggrandized cell viability compared with the control group. In contrast, miRNA-146 inhibition decreased cell viability. These results showed that up-regulation of miRNA-146 significantly enhanced the viability of LPS-treated ovarian granulosa cells. LPS suppressed cells viability in ovarian granulosa cells dose-dependent manner, with statistically significant effects at 12 µg/mL (P < 0.01) and at 16 µg/mL (P < 0.01) concentrations. Thus, 12 µg/mL was selected as LPS-stimulating condition for use in the following investigations.

The viability of granulosa cells was determined by the effect on granulosa cells at different concentrations of LPS (4, 8, 12, 16, 20 µg/mL), *P < 0.05; **P < 0.01; ***P < 0.001.

**Up-regulation of miRNA-146 in granulosa cells and transfection efficiency**

The transfection efficiency of miRNA-146 was used to evaluate by qRT-PCR in LPS-treated granulosa cells transfected with miRNA-146 mimics, miRNA-146 inhibitors, or negative control (NC). As demonstrated in Figure 2a, it was observed that in granulosa cells, miRNA-146 mimic remarkable enhanced the levels of miRNA-146 expression (P < 0.01), and miRNA-146 inhibitor remarkable reduced the levels of miRNA-146 expression (P < 0.01). These experimental data indicated that the levels of miRNA-146 expression in granulosa cells are successfully up-regulation, promoted cell viability. In addition, we found that LPS-treated granulosa cells were repressed by transfection miRNA-146 mimics (shown in Figure 2a). The percentage of apoptotic cells by TUNEL detected in granulosa cells was raised in the LPS group compared with the control group, indicating a relative higher apoptosis degree. There was a significant reduction in the miRNA-146 group compared with the LPS group by TUNEL assay, demonstrating an anti-apoptotic effect of up-regulation miRNA-146 expression (shown in Figure 2c-d).

Figure 2b: granulosa cells were transfected with miRNA-146 mimics (30 nmol/L), miR-146 inhibitor (30 nmol/L), or negative control group (NC), and then treated with a concentration of 10 µg/ml LPS for 12 hours. At 12, 24, 36, and 48 hours after LPS exposure, the viability of granulosa cells was measured by MTT assay. * P < 0.05; ** P < 0.01.

Figure 2c-d): The apoptotic cell rate was measured by TUNEL assay, ** P < 0.01; *** P < 0.001.

**Up-regulation of miRNA-146 suppresses TNF-a and IL-6 expression by LPS-induced granulosa cells**

In POI, inflammatory response and oxidative stress were involved inflammatory factors. Therefore, we investigated the effect of miRNA-146 on the expression of inflammatory cytokines leukin-6 (IL-6), and TNF-a in LPS-treated granulosa cells. The expression levels of IL-6 and TNF-a in the transfected granulosa cells were detected by using western blotting. As a result, compared with the control group, miRNA-146 mimic suppressed the levels of TNF-a and IL-6 expression. We further measured the expression of TNF-a and IL-6, which were shown significantly increased by LPS-induced in the miRNA-146 inhibitor group and LPS group and LPS+NC group (Figure 3). These data indicate that up-regulation of miRNA-146 can protect granulosa cells from LPS-induced inflammation response by negatively regulating TNF-a and IL-6 secretion.

Figure 3a-b: The levels of miRNA-146 expression and IL-6, and TNF-a expression in granulosa cells. Granulosa cells were transfected with miRNA-146 mimics, miRA-146 inhibitors, or negative control (NC) and were treated using concentration of
10 μg/mL LPS for 12 h. The levels of IL-6 and TNF-α expression in the LPS-treated granulosa cells were measured by qRT-PCR and Western blot analysis.* P < 0.05; ** P < 0.01; *** P < 0.001.

**Up-regulation of miRNA-146 relieves apoptosis of LPS-induced granulosa cells**

The effects of levels the miRNA-146 expression on cell apoptosis was performed to be determined by TUNEL assay in granulosa cells. As our results demonstrated, it has been observed that the percentage of apoptotic granulosa cells was significantly greater following LPS stimulation and transfection with miRNA-Control group (P < 0.05). This underlying mechanism of apoptosis granulosa cells was further discussed is the levels of Bax and Bcl-2 expression. Our results showed that the up-regulation of miRNA-146 increased significantly reduced the levels of Bax protein expression and significantly exaggerated the levels of Bcl-2 (Figure 4a-b). The study demonstrated that up-regulation of miRNA-146 expression repress apoptosis of granulosa cells by reducing Bax and exaggerating Bcl-2. Moreover, we studied the effect of miRNA-146 on apoptosis and the expression of IL-6 and TNF-a in LPS-treated granulosa cell. And TNF-a and IL-6 were significantly decreased in the LPS+miR-146 mimics group, which indicates the alleviated
apoptosis status of granulosa cells. On the contrary, LPS+ miRNA-146 inhibitors group, the TNF-a and IL-6 expression was significantly up-regulation. The up-regulation of miRNA-146 could decrease the levels of IL-6 and TNF-a expression in granulosa cells, in contrary, down-regulation of miRNA-146 significantly enhanced the levels of these inflammatory factors IL-6 and TNF-a expression (Figure 3a-c). Our results suggested that up-regulation of miRNA-146 could inhibit apoptosis of granulosa cells and demonstrate an anti-apoptotic effect of up-regulation of miRNA-146 expression.

The up-regulation of miRNA-146 suppresses TLR4/NF-κB signaling pathway by LPS-induced granulosa cells

To further explore the effect of miRNA-146 protective against in the LPS-induced ovarian dysfunction, the protein levels of TLR4/NF-κB were detected. Thereafter, we studied the effect of up-regulation miRNA-146 expression on the oxidative stress response of TLR4 and NF-κB signal pathway proteins involved in apoptosis. Western blotting analysis were used to measure the expression of protein expression levels of TLR4 and NF-κB in LPS-induced ovarian granulosa cells. These results showed that the up-regulation of miRNA-146 was significantly reduced expression level of TLR4 and NF-κB, compared with negative control group in LPS-induced ovarian dysfunction (Figures 5). In contrast, the effect of miRNA-146 inhibitory was promoted the increase of expression level of TLR4 and NF-κB, compared with that of NC group (P < 0.01, Figures 5a-b). In addition, we also confirmed that miRNA-146 targeted siRNA for the expression of silenced TLR4. The results showed that up-regulation of miRNA-146 expression decreased the levels of TLR4 and NF-κB expression. This study suggested that down-regulation TLR4 and NF-κB are important for the effect of up-regulation miRNA-146 expression protects against LPS-induced ovarian dysfunction.

The underlying TLR4/NF-κB signaling pathway closely associated with the effects of miRNA-146 expression on ovarian dysfunction, which was investigated. However, the levels of TLR4 and NF-κB expression were analyzed following, then up-regulation of miRNA-146 by western blotting assay.

**Discussion**

Premature ovarian failure and infertility are difficult problems in clinical treatment. There are no any specific drugs and effective treatment measures at present. Even stem cell therapy is limited by some conditions [17]. POI is induced commonly animal models of using various chemicals and chemotherapy. Most studies have used busulfan, such as: cyclophosphamide and ZP3, as well as surgically removed of ovarian, and gene knockout mice are used to study ovarian dysfunction, ovarian failure, ovarian damage and the effect of stem cells [18,19]. However, there are still controversial for these therapeutic effects of stem cells because of the differences between model animals and humans [20]. In this study, a LPS-induced ovarian

![Figure 5](image-url)
dysfunction of POI model was established to investigate the miRNA-146 restore ovarian function in POI. This LPS-induced POI model has establishment of humanized immunity and the characteristics of inflammatory response and oxidative stress, which is different from several traditional POI animal models [17–20]. In this LPS-induced POI model, we found that E2 concentrations were meaningfully lower and FSH concentrations are meaningful higher compared with control group. The results of this study demonstrated the effect of LPS on the hypothalamus-pituitary-ovarian axis [13]. In vivo, after injection of miRNA-146 mimics, it was observed that the FSH concentrations and the levels of LPS and ROS expression were significantly down-regulated and E2 concentrations were significantly up-regulated. Therefore, our data supported that the up-regulation miRNA-146 expression may regulated ovarian hormones and reversed of ovarian function [21]. Furthermore, previous study showed that intravenously injected bone marrow-derived mesenchymal stem cells (BMMSCs) reached the ovaries of FOR knock out mice, differentiated and expressed the FSH receptor, thereby regulating FSH levels and estrogen production and promoting activate folliculogenesis [22]. To these ends, we analyzed in vivo data from LPS-induced POI mouse model and performed in vitro experiments to validate our proposed the effect of miRNA-146 protective against ovarian dysfunction mechanisms.

miRNA-146 family members are called inflammatory inducible miRNAs, which participate in the negative feedback regulation of toll-like receptors (TLRs) signal and induce inflammatory response. It is closely related to atherosclerosis and the occurrence and development of cardiovascular diseases [23]. Recent studies have shown that miRNA-146 can reduce premature ovarian failure in mice, and miRNA-146 overexpression can inhibit DAB2IP/ASK1/p38 MAPK pathway and γH2A. X phosphorylation alleviates mouse involvement in the process of oocyte proliferation and apoptosis [16]. Our animal experiments showed that up-regulation of miRNA-146 can increase the ovarian granulosa cells viability by LPS-induced granulosa cells which showed the study of the viability of ovarian granulosa cells treated with different concentrations of LPS for 12, 24, 36, and 48 hours (Figure 1). At present, stem cell therapy for POI is to transplant into ovarian granulosa cells and improve the vitality of cell growth and proliferation [24]. Furthermore, the expression of miRNA-146 was down-regulated in patients with POI, while the expressions of IL-6 and TNF-α were up-regulated, suggesting that miRNA-146 can regulated TLR4 and NF-κB signaling pathway in response to foreign inflammatory response in a negative feedback manner by binding target genes to inflammatory factors such as TNF-α and IL-6 [25]. In our study, up-regulation of miRNA-146 decreased the presence of IL-6 and TNF-α in granulosa cells (Figure 3), suggesting that down-regulation of the expression level of miNAR-146 and high-level expression of IL-6 and TNF-α is involved in the occurrence and development of POI, which was chronic low-grade inflammation [26]. In the study, we confirmed that up-regulated miRNA-146 has anti-inflammatory and anti-oxidant effects in POI. In previous studies, miRNA-146 inhibited the expression of TNF-α and IL-6 in septic vascular endothelial cells [27].

In POI, TNF-α and IL-6 are released, resulting into induction of apoptosis [28]. Therefore, we investigated whether the increased of up-regulation of miRNA-146 expression could inhibit apoptosis in granulosa cells of POI. Recent study reports that another therapeutic mechanism to prevent ovarian failure is to inhibit granulosa cells apoptosis, human placenta-derived mesenchymal stem cells (hPSCs) can inhibit granulosa cells apoptosis by modulating stress levels controlled by the IRE1-a pathway [29]. One of the newest therapeutic approaches is to use stem cells extracted from human menstrual blood [30]. And the successful engraftment of mesenchymal stem cells was transplanted into the ovaries of cyclophosphamide (CTX)-induced POI model mice [31]. However, further studies are necessary to identify possible differences in mesenchymal stem cells between normal donors and POI patients [19,20].

The recently research shows that POI are closely related to inflammatory response [32]. The latest study has shown that the increase of the expression level of miRNA-146 can inhibit the expression level of TNF-α and IL-6 and reduce the risk of
covid-19 [33]. Several studies have shown the paracrine activity of stem cells by identifying exosomal miRNAs from stem cells in fetal tissues and studying their target genes [34,35]. Exosomes derived from amniotic fluid stem cells contain miRNA-146, which inhibit granulosa cells apoptosis by regulating target genes [36]. miRNAs are also used to enhance the outcome of mesenchymal stem cells transplantation by regulating granulosa cells viability [37].

In our studies, the increase of inflammatory factors IL-6 and TNF-a leads to the apoptosis of granulosa cells. On the contrary, it reduces the expression of IL-6 and TNF-a and can improve LPS-induced apoptosis in granulosa cells; it is suggesting that the reduction of inflammatory response may be related to the improvement ovarian function of POI [38]. At the same time, some studies have confirmed that inflammatory factors may be used as independent biomarkers in POI patients [39]. Consistently, our results showed that the expression of IL-6 and TNF-a is a key regulator of the occurrence and development of POI. Therefore, we evaluated the effects of miRNA-146 on the expression of IL-6 and TNF-a affects the apoptosis of granulosa cells. Collectively, LPS/TLR4/NF-κB signaling pathway can be negatively regulated by miRNA-146 in innate immune responses [40], and miRNA-146 has been demonstrated to be negative regulation induced by LPS via TLR4/ NF-κB signaling pathway [41]. Additionally, Bax Knock out mice show improved ovarian function, which typically decreases because of age-related issues [42]. The proapoptotic gene Bax is related to aging [43]. Moreover, Bcl-2 is involved in the regulation of granulosa cells apoptosis. Bcl-2 can reduce granulosa cells apoptosis by antioxidant pathway [44]. Meanwhile, overexpression of Bcl-2 could resist the level of Bax, which decreases granulosa cell apoptosis through regulated estrogen hormone metabolism [45]. Our results demonstrated that significantly increased Bcl-2 expression and significantly reduced the levels of Bax expression in miRNA-146 mimic group, whereas protein expression of Bax significantly enlarged in miRNA-146 inhibitor group. The mechanism underlying overexpression of miRNA-146 attenuated granulosa cells apoptosis, in which miRNA-146 play a role of anti-apoptotic that may be by up-regulation of Bcl-2 expression and down-regulation of Bax expression in LPS-induced granulosa cells [46].

To further identify the protective role and function of miRNA-146, we evaluated the level of TLR4 and NF-κB as well as siTLR4 expression, siTLR4 was used for investigation of the relationship between miRNA-146 and TLR4 in LPS-induced ovarian dysfunction. In our study, it is shown that TLR4 and NF-κB can up-regulate the expression of LPS, ROS and significantly enlarge the oxidative stress and inflammatory response, which suggested TLR4 and NF-κB are proinflammatory factor any [47]. So far, there is no report of NF-κB signal that plays a crucial role in chronic inflammatory failure of POI. In this study, we first time demonstrated that overexpression of miRNA-146 decreased NF-κB expression, which can stimulate the expression of inflammatory factors, such as TNF-α and IL-1β, and by trigger TLR4/ NF-κB signaling pathways. NF-κB, as a transcription factor, which is the main feature of chronic inflammatory diseases in cell proliferation, apoptosis, and immune reaction. In current study, we first time demonstrated that up-regulation of miRNA-146 expression decreased TLR4/ NF-κB expression in mouse model of POI. This results displayed that miRNA-146 significantly depressed TLR4/ NF-κB signaling pathways. It is suggested that the expression of miRNA-146 plays protective against ovarian dysfunction.

Finally, we have investigated the molecular mechanism of miRNA-146 regulating silencing TLR4 (siTLR4). siTLR4 can regulate apoptosis in response to oxidation and oxidative damage, which may be a regulatory molecule against apoptosis and anti-inflammatory. By detecting the expression level of siTLR4, it was found that siTLR4 significantly up-regulated the expression level of miRNA-146 in granulosa cells. These studies suggest that siTLR4 in granulosa cells inhibits apoptosis and inflammation by up-regulating the expression of miRNA-146. In addition, we also showed that siTLR4 expression could reverse the inhibitory effect of miRNA-146. Other studies have also explored the effect of miRNA-146 on TLR4 expression, miR-146 directly targets TNF-α /NF-κB in cardiomyocytes, resulting in decreased myocardial dysfunction [48].
From the present results, miRNA-146 was significantly overproduced with the activation of siTLR4 in LPS-treated granulosa cells and the transfection of miRNA-146 mimics significantly reduced the expression of TLR4 and NF-κB. These study suggest that miRNA146 plays a protective role might be inhibiting TLR4 and NF-κB signaling pathways and up-regulation of siTLR4 expression. TLRs are innate immune transmembrane receptors and signal transduction receptors found in recent years, and initiate natural immune response by binding with ligands. TLR4 is a pattern recognition receptors involved in chronic inflammation, oxidative stress and the formation of tumor microenvironment. After TLR4 recognizes the corresponding ligands, they activate NF-κB by activating a series of signal transduction molecules pathway that mediates immune responses such as inflammatory response and oxidative stress [49]. TLR4 exists in the ovary and reproductive tract, and TLR4 is also involved in inducing apoptosis of ovarian granulosa cells in uterine inflammatory diseases [50]. In summary, our experimental results are expected to achieve the effect of stem cell therapy, in the future, we will increase clinical case studies to confirm. This study is safe and reliable, sufficient sources and without ethical issues and it will not involve the occurrence of ovarian granulosa cell tumor. A recent study shows that autologous stem cell may improve the conditions in patients with POI [51]; however, only one patient had a spontaneous pregnancy, while most patients were subjected to in vitro fertilization cycles [52]. In addition oocytes extracted from these POI mice after stem cell transplantation were difficult to fertilize with healthy sperm in vitro. This finding is the current limitations in applying this stem cell therapy to IVF [53,54]. However, there are many ethical concerns with the use of these current stem cells are difficult to source. Therefore, the study of stem cells is still at the very early stage, and thus, they are not usually used in clinically [55–57].

Conclusion
In conclusion, the present study revealed that the effect of miRNA-146 protects against from LPS-induced ovarian dysfunction and granulosa cell apoptosis and inflammatory response. miRNA-146 may play a protective role by inhibiting TLR4/NF-κB signaling pathway and down-regulating TNF-a and IL-6. The findings in the current study suggest that miRNA-146 can be used as an immunomodulatory factor and a novel target for the treatment of POI.

Disclosure statement
The authors declared that they do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Funding
This work was supported by Major Project of Regional collaborative Fund of Foundational and Basic Research for Application of Guangdong Province (No. 2020b15120009).

References
[1] Prosper I, Abdeljabar EA, Ujalla S, et al. Intraovarian injection of autologous human mesenchymal stem cells increases estrogen production and reduces menopausal symptoms in women with premature ovarian failure: two case reports and a review of the literature. J Med Case Rep. 2020;14(1):108.
[2] Giri R, Vincent AJ. Prevalence and Risk Factors of Premature Ovarian Insufficiency/ Early Menopause. Semin Reprod Med. 2020;38(4–05):237–246.
[3] Tatang C, Arredondo-Bisonó T, Bergamasco A, et al. Human Papillomavirus Vaccination and Premature Ovarian Failure: a Disproportionality Analysis Using the Vaccine Adverse Event Reporting System. Drugs Real World Outcomes. 2022;9(1):79–90.
[4] Deng T, Jing H, Yao Q, et al. Human Umbilical Cord Mesenchymal Stem Cells Improve Ovarian Function in Chemotherapy-Induced Premature Ovarian Failure Mice Through Inhibiting Apoptosis and Inflammation via a Paracrine Mechanism. Reprod Sci. 2021;28(6):1718–1732.
[5] Nahand J, Karimzadeh MR, Nezamnia M, et al. The role of miR-146a in viral infection. IUBMB Life. 2020;72(3):343–360.
[6] LB Z, XY G, Jp G, et al. Notoginsenoside R1 upregulates miR-221-3p expression to alleviate ox-LDL-induced apoptosis, inflammation, and oxidative stress by inhibiting the TLR4/NF-κB pathway in HUVECs. Journal of Medical and Biological Research. 2020;53(6): e9346
[7] Zhang J, Xu Y, Liu H, et al. MicroRNAs in ovarian follicular atresia and granulosa cell apoptosis. Reprod Biol Endocrinol. 2019;17(1):9
[8] Wang Q, Li D, Han Y, et al. MicroRNA-146 protects A549 and H1975 cells from LPS-induced apoptosis and inflammation injury. J Biosci. 2017;42(4):637–645.

[9] Fumie M. Lipopolysaccharide-induced mechanisms of ovarian dysfunction in cows with uterine inflammatory diseases. J Reprod Dev. 2020;66(4):311–317.

[10] Wang X, Li C, Wang Y, et al. UFL1 Alleviates LPS-Induced Apoptosis by Regulating the NF-kappaB Signaling Pathway in Bovine Ovarian Granulosa Cells. Biomolecules. 2020;10(2):260.

[11] Xie Y, Zhang K, Zhang K, et al. Toll-like receptors and high mobility group box 1 in granulosa cells during bovine follicle maturation. J Cell Physiol. 2020;235(4):3447–3462.

[12] Yang M, Wang X, Wang L, et al. IL-1alpha Up-Regulates IL-6 Expression in Bovine Ovarian Granulosa Cells via MAPKs and NF-kappaB Signaling Pathways. Cell Physiol Biochem. 2017;41(1):265–273.

[13] Li R, Ma C, Xiong Y, et al. An Antagonistic Peptide of Gpr1 Ameliorates LPS- Induced Depression through the Hypothalamic-Pituitary-Ovarian. Axis. Biomolecules. 2021;11(6):857.

[14] Bidne KL, Kvidera SS, Ross JW, et al. Impact of repeated lipopolysaccharide administration on ovarian signaling during the follicular phase of the estrous cycle in post-pubertal pigs. J Anim Sci. 2018;96(9):3622–3634.

[15] Cakiroglu Y, Saltik A, Yuceturk A, et al. Effects of intravarian injection of autologous platelet rich plasma on ovarian reserve and IVF outcome parameters in women with primary ovarian insufficiency. Aging (Albany NY). 2020;12(11):10211–10222.

[16] Te Liu J, Chen C, Chen C, et al. MicroRNA-146b-5p overexpression attenuates premature ovarian failure in mice by inhibiting the Dab2ip/Ask1/p38-Mapk pathway and γH2A.X phosphorylation [J]. Cell Prolif. 2021;54(1):e12954.

[17] Takahashi A, Yousif A, Hong L, et al. Premature ovarian insufficiency: pathogenesis and therapeutic potential of mesenchymal stem cell. J Mol Med (Berl). 2021;99(5):637–650.

[18] Nahideh NY, Reza R, B AM, et al. Menstrual blood CD146+ mesenchymal stem cells reduced fibrosis rate in the rat model of premature ovarian failure. Cell Biochem Funct. 2021;39(8):998–1008.

[19] Shahin A, Mahdi M, Mohammad P, et al. Effectiveness of Stem Cell Therapy in the Treatment of Ovarian Disorders and Female Infertility: a Systematic Review. Curr Stem Cell Res Ther. 2020;15(2):173–186.

[20] Na J, Kim GJ. Recent trends in stem cell therapy for premature ovarian insufficiency and its therapeutic potential: a review. J Ovarian Res. 2020;13(1):74.

[21] Zhang H, Luo Q, Lu X, et al. Effects of hPMSCs on granulosa cell apoptosis and AMH expression and their role in the restoration of ovary function in premature ovarian failure mice. Stem Cell Res Ther. 2018;9(1):20.

[22] Zhi Z, Wei X, Jingming X, et al. Bone marrow-derived mesenchymal stem cells (BM-MSCs) inhibit apoptosis of spinal cord cells in a kaolin-induced syringomyelia-associated scoliosis rabbit model. Int J Clin Exp Pathol. 2018 Apr 1;11(4):1890–1899.

[23] Gao N, Dong L. MicroRNA-146 regulates the inflammatory cytokines expression in vascular endothelial cells during sepsis. Pharmazie. 2017;72(11):700–704.

[24] Zhou Y, Zhou J, Xu X, Xu X, et al. Matrigel/Umbral Cord-Derived Mesenchymal Stem Cells Promote Granulosa Cell Proliferation and Ovarian Vascularization in a Mouse Model of Premature Ovarian Failure. Stem Cells Dev. 2021;30(15):782–796.

[25] Diaojuan W, Yajing W, Yaling Z, et al. Exposure to hyperandrogen drives ovarian dysfunction and fibrosis by activating the NLRP3 inflammasome in mice. Sci Total Environ. 2020;745:141049.

[26] Karunakaran D, Nguyen MA, Geoffrion M, et al. RIPA1 Expression Associates With Inflammation in Early Atherosclerosis in Humans and Can Be Therapeutically Silenced to Reduce NF-kappaB Activation and Atherogenesis in Mice. Circulation. 2021;143(2):163–177.

[27] Gao N, Dong L. MicroRNA-146 regulates the inflammatory cytokines expression in vascular endothelial cells during sepsis. Pharmazie. 2017;72(11):700–704.

[28] Zhang C, Ma K, Yang Y, et al. Glauocalyx A suppresses inflammatory responses and induces apoptosis in TNF-a-induced human rheumatoid arthritis via modulation of the STAT3 pathway. Chem Biol Interact. 2021;341:109451.

[29] Li H, Zhao W, Wang L, et al. Human placenta-derived mesenchymal stem cells inhibit apoptosis of granulosa cells induced by IRE1alpha pathway in autoimmune POF mice. Cell Biol Int. 2019;43(8):899–909.

[30] Sklučė G, Bausytė R, Borutinskaitė V, et al. Menstrual Blood-Derived Endometrial Stem Cells’ Impact for the Treatment Perspective of Female Infertility. Int J Mol Sci. 2021;22(13):6774.

[31] Ding C, Zhu L, Shen H, et al. $\&$ Exosomal miRNA-17-5p derived from human umbilical cord mesenchymal stem cells improves ovarian function in premature ovarian insufficiency by regulating SIRT7[J]. Stem Cells. 2020;38(9):1137–1148.

[32] Yusuf C, Salih K, Ali O, et al. Prediction of Lipoprotein-Associated Phospholipase A2 and Inflammatory Markers in Subclinical Atherosclerosis in Premature Ovarian Failure Patients. [J] Acta Cardiol Sin. 2021;37(1):30–37.

[33] Roganović J. Downregulation of microRNA-146a in diabetes, obesity and hypertension may contribute to severe COVID-19. Med Hypotheses. 2021;146:110448.

[34] Fu X, He Y, Wang X, et al. Overexpression of miR-21 in stem cells improves ovarian structure and function in rats with chemotherapy-induced ovarian damage by targeting PDCD4 and PTEN to
inhibit granulosa cell apoptosis. Stem Cell Res Ther. 2017;8(1):187.

[35] Sun B, Ma Y, Wang F, et al. miR-644-5p carried by bone mesenchymal stem cell-derived exosomes targets regulation of p53 to inhibit ovarian granulosa cell apoptosis. Stem Cell Res Ther. 2019;10(1):360.

[36] Xiao GY, Cheng CC, Chiang Y-S, Chiang YS, et al. Exosomal miR-10a derived from amniotic fluid stem cells preserves ovarian follicles after chemotherapy. Sci Rep. 2016;6(1):23120.

[37] Ding C, Zhu L, Shen H, et al. Exosomal miRNA-17-5p derived from human umbilical cord mesenchymal stem cells improves ovarian function in premature ovarian insufficiency by regulating SIRT7. Stem Cells. 2020;38(9):1137–1148.

[38] Abraham Gnanadass S, Divakar Prabhu Y, Valsala Gopalakrishnan A. Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update. Arch Gynecol Obstet. 2021;303(3):631–643.

[39] Pavel DC, Brandon MM, Sonia AL, et al. TNF-α-driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. Blood. 2019;134(9):727–740.

[40] Ma H, Dong Y, Sun K, et al. Protective effect of MiR-146 on renal injury following cardiopulmonary bypass in rats through mediating NF-kappaB signaling pathway. Bioengineered. 2022;13(1):593–602.

[41] Feng J, Zhu Y, Chen L, et al. Clinical Significance of microRNA-146a in Patients with Ulcerative Colitis. Ann Clin Lab Sci. 2020;50(4):463–467.

[42] Zheng Y, Ma L, Liu N, et al. Autophagy and Apoptosis of Porcine Ovarian Granulosa Cells During Follicular Development. Animals (Basel). 2019 Dec 10;9(12):1111.

[43] Yin N, Wu C, Qiu J, et al. Protective properties of heme oxygenase-1 expressed in umbilical cord mesenchymal stem cells help restore the ovarian function of premature ovarian failure mice through activating the JNK/Bcl-2 signal pathway- regulated autophagy and upregulating the circulating of CD8(+)CD28(-) T cells. Stem Cell Res Ther. 2020;11(1):49.

[44] Yang H, Xie Y, Yang D, et al. Oxidative stress-induced apoptosis in granulosa cells involves JNK, p53 and Puma. Oncotarget. 2017;8(15):25310–25322.

[45] Gong Y, Luo S, Fan P, et al. Growth hormone activates PI3K/Akt signaling and inhibits ROS accumulation and apoptosis in granulosa cells of patients with polycystic ovary syndrome. Reprod Biol Endocrinol. 2020;18(1):121.

[46] Ferranti EM, Aloqaily BH, Gifford CA, et al. Effects of lipopolysaccharide on beta-catenin, aromatase, and estrogen production in bovine granulosa cell in vivo and in vitro. Domest Anim Endocrinol. 2022;78:106652.

[47] Karunakaran D, Nguyen MA, Geoffrion M, et al. RIPK1 Expression Associates With Inflammation in Early Atherosclerosis in Humans and Can Be Therapeutically Silenced to Reduce NF-kappaB Activation and Atherogenesis in Mice. Circulation. 2021;143(2):163–177.

[48] Zhang W, Shao M, He X, et al. Overexpression of microRNA-146a protects against oxygen-glucose deprivation/recovery-induced cardiomyocyte apoptosis by inhibiting the NF-kB/TNF-α signaling pathway. Mol Med Rep. 2018;17(1):1913–1918.

[49] Yang Y, Yang L, Cao Q, et al. Cryptotanshinone alleviates polycystic ovary syndrome in rats by regulating the HMGB1/TLR4/NF-kB signaling pathway [J]. Mol Med Rep. 2020;22(5):3851–3861.

[50] Xie Y, Zhang K, Zhang K, et al. Toll-like receptors and high mobility group box 1 in granulosa cells during bovine follicle maturation. J Cell Physiol. 2020;235(4):3447–3462.

[51] Gupta S, Lodha P, Karthick MS, et al. Role of Autologous Bone Marrow- Derived Stem Cell Therapy for Follicular Recruitment in Premature Ovarian Insufficiency: review of Literature and a Case Report of World’s First Baby with Ovarian Autologous Stem Cell Therapy in a Perimenopausal Woman of Age 45 Year. J Hum Reprod Sci. 2018;11(2):125–130.

[52] Hikabe O, Hamazaki N, Nagamatsu G, et al. Reconstitution in vitro of the entire cycle of the mouse female germ line. Nature. 2016;539(7628):299–303.

[53] Sciorio R, Tramontano L, Catt J. Preimplantation genetic diagnosis (PGD) and genetic testing for aneuploidy (PGT-A): status and future challenges. Gynecol Endocrinol. 2020;36(1):6–11.

[54] Totonchi M, Babaabasi B, Najafi H, et al. Preimplantation Genetic Screening and The Success Rate of In Vitro Fertilization: a Three-Years Study on Iranian Population. Cell J. 2021;22(4):467–475.

[55] Fu YX, Ji J, Shan F, et al. Human mesenchymal stem cell treatment of premature ovarian failure: new challenges and opportunities. Stem Cell Res Ther. 2021;12(1):161.

[56] Yoon SY, Yoon JA, Park M, et al. Recovery of ovarian function by human embryonic stem cell-derived mesenchymal stem cells in cisplatin-induced premature ovarian failure in mice. Stem Cell Res Ther. 2020;11(1):255.

[57] Jiang Y, Zhang Z, Cha L, et al. Resveratrol Plays a Protective Role against Premature Ovarian Failure and ProZmpts Female Germline Stem Cell Survival. Int J Mol Sci. 2019;20(14):3605.